Physician profile
Ronald Irwin Weitzner
NPI 1942285937
$7,320.34
in general payments reported to CMS, 2019-2025
26 companies · $293 in 2025
The $293 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,505 · 2020: $1,490 · 2021: $460 · 2022: $1,023 · 2023: $987 · 2024: $562 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,842.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,105.35 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $851.98 | 2019-2025 | |
| Amgen INC. | $699.46 | 2019-2023 | Tavneos |
| Glaxosmithkline, LLC. | $545.66 | 2019-2023 | Benlysta |
| Pfizer INC. | $500.73 | 2019-2023 | |
| Janssen Biotech, INC. | $449.73 | 2019-2023 | Simponi Aria |
| Boehringer Ingelheim Pharmaceuticals, INC. | $372.16 | 2019-2024 | Spevigo |
| Ucb, INC. | $368.81 | 2019-2024 | |
| Lilly USA, LLC | $359.65 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $329.87 | 2021-2023 | Saphnelo |
| Horizon Therapeutics Plc | $306.30 | 2019-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $287.49 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $269.23 | 2020-2025 | Tremfya |
| Genzyme Corporation | $243.85 | 2019-2024 | |
| Genentech USA, INC. | $124.11 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $111.76 | 2022 | |
| Celgene Corporation | $83.06 | 2019 | |
| Sobi, INC | $77.31 | 2019-2021 | |
| Medtronic USA, INC. | $62.94 | 2019 | |
| Radius Health, INC. | $36.83 | 2019 | |
| Fidia Pharma USA INC. | $36.48 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $24.67 | 2020 | |
| Sebela Pharmaceuticals INC. | $19.96 | 2019 | |
| Hikma Pharmaceuticals USA | $19.96 | 2019 | |
| Merck Sharp & Dohme LLC | $17.60 | 2020 | |
| Mallinckrodt Enterprises LLC | $15.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Weitzner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.